RU97117163A - INTRODUCED BY INJECTION ONCE TIME IN MONTH, THE COMPOSITION AS A CONTRACEPTIVE OF LONG-TERM ACTION AND IN HORM-REPLACING THERAPY FOR PERI- AND PRE-PAINHOUSAL WOMEN - Google Patents

INTRODUCED BY INJECTION ONCE TIME IN MONTH, THE COMPOSITION AS A CONTRACEPTIVE OF LONG-TERM ACTION AND IN HORM-REPLACING THERAPY FOR PERI- AND PRE-PAINHOUSAL WOMEN

Info

Publication number
RU97117163A
RU97117163A RU97117163/14A RU97117163A RU97117163A RU 97117163 A RU97117163 A RU 97117163A RU 97117163/14 A RU97117163/14 A RU 97117163/14A RU 97117163 A RU97117163 A RU 97117163A RU 97117163 A RU97117163 A RU 97117163A
Authority
RU
Russia
Prior art keywords
component
peri
women
estradiol
painhousal
Prior art date
Application number
RU97117163/14A
Other languages
Russian (ru)
Inventor
Лахнит-Фиксзон Урсула
Айдинлик Семирамис
Original Assignee
Шеринг Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Шеринг Аг filed Critical Шеринг Аг
Publication of RU97117163A publication Critical patent/RU97117163A/en

Links

Claims (5)

1. Применение вводимой путем инъекции один раз в месяц композиции, содержащей эстрогенный и гестагенный компоненты в качестве биологически активных веществ для получения лекарственного средства для контрацепции и одновременной гормонзаменяющей терапии для пери- и предменопаузальных женщин.1. The use of a once-monthly injectable composition containing estrogen and progestogen components as biologically active substances for the manufacture of a medication for contraception and simultaneous hormone replacement therapy for peri- and premenopausal women. 2. Применение по п.1, отличающееся тем, что эстрогенный компонент выбирают из группы соединений, состоящей из 17β-эстрадиола, эстрадиол-3-бензоата, эстрадиол-17-валерата, -ципионата, -ундецилата, -энантата, а также других сложных эфиров эстрадиола. 2. The use according to claim 1, characterized in that the estrogen component is selected from the group of compounds consisting of 17β-estradiol, estradiol-3-benzoate, estradiol-17-valerate, β-cypionate, β-undecylate, β-enanthate, as well as other complex Estradiol esters. 3. Применение по п.1, отличающееся тем, что гестагенный компонент выбирают из группы соединений, состоящей из норэтистеронацетата, норэтистеронэнантата, медроксипрогестеронацетата, ципротеронацетата. 3. The use according to claim 1, characterized in that the progestogen component is selected from the group of compounds consisting of norethisterone acetate, norethisterone enanthate, medroxyprogesterone acetate, cyproterone acetate. 4. Применение по п.1, отличающееся тем, что эстрогенным компонентом является норэтистеронэнантат, а гестагенным компонентом является эстрадиолвалерат. 4. The use according to claim 1, characterized in that the estrogen component is norethisterone enanthate, and the progestational component is estradiolvalerate. 5. Применение по п.1, отличающееся тем, что эстрогенным компонентом является медроксипрогестеронацетат, а гестагенным компонентом является эстрадиолципионат. 5. The use according to claim 1, characterized in that the estrogenic component is medroxyprogesterone acetate, and the progestational component is estradiolcipionate.
RU97117163/14A 1995-03-16 1996-03-15 INTRODUCED BY INJECTION ONCE TIME IN MONTH, THE COMPOSITION AS A CONTRACEPTIVE OF LONG-TERM ACTION AND IN HORM-REPLACING THERAPY FOR PERI- AND PRE-PAINHOUSAL WOMEN RU97117163A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19510861.2 1995-03-16

Publications (1)

Publication Number Publication Date
RU97117163A true RU97117163A (en) 1999-08-10

Family

ID=

Similar Documents

Publication Publication Date Title
CN1033948C (en) Process for preparing dihydrosprironenon of antiandrogen
RU2091069C1 (en) Agent for hormonal contraception that inhibits ovulation
DE69118494T2 (en) Contraception procedure and scheme
KR920011517A (en) Low Estrogen Oral Contraceptives
RU96119957A (en) PHARMACEUTICAL COMBINED DRUG FOR HORMONAL CONTRACEPTION
RU96119803A (en) COMBINED DRUG FOR CONTRACEPTION BASED ON NATURAL ESTROGENS
RU96100843A (en) COMPOSITION BASED ON SUGAR FOR APPLICATION ON A TABLET, PRESSED TABLET
RU96118462A (en) Transdermal Therapy Systems Containing Sex Steroids
KR960028919A (en) Regulated release of steroids from saccharide coatings
RU96115196A (en) COMPOSITION FOR CONTRACEPTION
KR970069031A (en) Pharmaceutical tablets with controlled release of steroids from sugar coating
DK365887D0 (en) COMBINATION DOSAGE FOR HORMONE TREATMENT OF WOMEN IN PRAE-MENOPAUSUS
RU2001129160A (en) Intermittent hormone replacement therapy with low doses of estrogen
KR970704450A (en) Use of a progesterone antagonist and gestagen to treat endometrial hyperplasia or uterine leiomyoma (Use of a Progesterone Antagonist and a Gestagen for Endometriosis or Leiomyomate Uteri)
Sakiz et al. A new approach to estrogen-free contraception based on progesterone receptor blockage by mid-cycle administration of ethyl norgestrienone (R 2323)
RU97117163A (en) INTRODUCED BY INJECTION ONCE TIME IN MONTH, THE COMPOSITION AS A CONTRACEPTIVE OF LONG-TERM ACTION AND IN HORM-REPLACING THERAPY FOR PERI- AND PRE-PAINHOUSAL WOMEN
GB1462893A (en) Method for fertile breeding control in female bovine
EP0889727B1 (en) Sequential oestrogen/progesterone antagonist combination for hormone replacement therapy
RU1789216C (en) Composition showing contraceptive effect
NZ304027A (en) Once a month injectable contraceptive comprising an estrogenic and gestagenic component for contraception and simultaneous hormone replacement therapy
Hall Once-a-month injectable contraceptives
ES363068A1 (en) 11beta-CHLORO-19-NOR-STEROIDS
RU2000118225A (en) Subcutaneous Introduction of Medroxyprogesterone Acetate for the Treatment of Menopause and Endometriosis
RU97103327A (en) APPLICATION OF A COMBINED PRODUCT CONTAINING A COMPETING PROGESTERON AND HESTAGEN ANTAGONIST TO PRODUCE A MEDICINE FOR THE TREATMENT OF ENDOMETRIOSIS OR LEIOMYOMATATER
GB1313659A (en) 9alpha-unsubstituted-11beta-chloro-19-norpregnane compounds